Endogenous tumor microenvironment-responsive multifunctional nanoplatforms for precision cancer theranostics

Ding, Shuizi; Wang, Shaoxiong; Shi, Zikuan; Pandey, Nil Kanatha; Chudal, Lalit; Wang, Lingyun; Zhang, Zijian; Wen, Yu; Yao, Hongliang; Lin, Liangwu; Chen, Wei; Li, Xiong

doi:10.1016/j.ccr.2020.213529

Cited by 25 publications

(16 citation statements)

References 393 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer stem cell biomarkers in HCC include CD133+, CD 49f+, CD90+, CD13, CD44, CD24, EPCAM, and SP 111 , 112 . To date, only CD113 and EPCAM have been used to target SOR-NPs to HCC stem cells 112 , 113 .…”

Section: Targeted and Responsive Delivery Of Sor With Npsmentioning

confidence: 99%

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. Sorafenib is an oral kinase inhibitor that inhibits tumor cell proliferation and angiogenesis and induces cancer cell apoptosis. It also improves the survival rates of patients with advanced liver cancer. However, due to its poor solubility, fast metabolism, and low bioavailability, clinical applications of sorafenib have been substantially restricted. In recent years, various studies have been conducted on the use of nanoparticles to improve drug targeting and therapeutic efficacy in HCC. Moreover, nanoparticles have been extensively explored to improve the therapeutic efficacy of sorafenib, and a variety of nanoparticles, such as polymer, lipid, silica, and metal nanoparticles, have been developed for treating liver cancer. All these new technologies have improved the targeted treatment of HCC by sorafenib and promoted nanomedicines as treatments for HCC. This review provides an overview of hot topics in tumor nanoscience and the latest status of treatments for HCC. It further introduces the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib.

show abstract

Section: Targeted and Responsive Delivery Of Sor With Npsmentioning

confidence: 99%

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9][10] The TME exhibits several distinguishable physiological features such as mildly acidic pH, hypoxia, high level of reactive oxygen species (ROS), excess levels of GSH, and overexpression of specific enzymes. [1][2][3][4][5] These features can be exploited as stimuli to induce specific changes in the chemical structures or physical properties of drugs to realize tumor-specific treatment with less side effects. [6][7][8][9][10] It is well-known that nanodrugs can be passively delivered to tumor sites through enhanced permeability and penetration (EPR) effects.…”

Section: Doi: 101002/advs202100074mentioning

confidence: 99%

“…More recently, tumor microenvironment (TME)‐responsive smart therapy systems have attracted increasing attention in the field of cancer therapy because they can take advantage of the difference between tumor and normal tissue microenvironments, thus decreasing side effects. [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ] The TME exhibits several distinguishable physiological features such as mildly acidic pH, hypoxia, high level of reactive oxygen species (ROS), excess levels of GSH, and overexpression of specific enzymes. [ 1 , 2 , 3 , 4 , 5 ] These features can be exploited as stimuli to induce specific changes in the chemical structures or physical properties of drugs to realize tumor‐specific treatment with less side effects.…”

Section: Introductionmentioning

confidence: 99%

“…The activatable photodynamic properties of Au-MB-PEG NPs were tested using 1,3-diphenylisobenzofuran (DPBF) to detect ROS generation in vitro. In the presence of HOCl-treated Au-MB-PEG NPs, the absorbance of DPBF at 410 nm rapidly decreased during 655 nm laser irradiation over 15 min, because of the generation of1 O 2 from the released MB photosensitizer (Figure 2C,D). In addition, the absorption decrease of DPBF was strongly dependent on the concentration of HOCl from 2 × 10 −6 to 10 × 10 −6 m at the same irradiation time for 10 min (Figure S17, Supporting Information), indicating the excellent 1 O 2 generation ability of HOCl-activated Au-MB-PEG NPs in vitro.…”

mentioning

confidence: 99%

See 1 more Smart Citation

HOCl‐Activated Aggregation of Gold Nanoparticles for Multimodality Therapy of Tumors

Liu

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Tumor microenvironment-responsive nanodrugs offer promising opportunities for imaging-guided precision therapy with reduced side effects. Considering that the antitumor effect is closely related to the size of the nanodrugs, it is particularly important to develop a therapeutic system with size adjustability in the tumor microenvironment, which is still a great challenge in the field of nanotheranostics. Herein, a reactive oxygen species (ROS)-activated aggregation strategy is reported for imaging-guided precision therapy of tumors. The ROS-activated nanoplatform is constructed based on gold nanoparticles (AuNPs) coated with an HOCl probe on its surface (namely, Au-MB-PEG NPs). The Au-MB-PEG NPs show high sensitivity toward HOCl, resulting in the modulation of surface charge and rapid aggregation of AuNPs, and simultaneous release of methylene blue as a photosensitizer for photodynamic therapy (PDT). In the tumor environment, the aggregated AuNPs ensure higher tumor accumulation and retention. Furthermore, the redshift of the absorption of aggregated AuNPs leads to activated photoacoustic imaging signals and photothermal therapy (PTT) under near-infrared irradiation. Au-MB-PEG NPs thus efficiently inhibit the tumor growth through combined PTT-PDT therapy. This work contributes to the design of stimuli-induced size-aggregation nanodrugs, thereby attaining advanced performance in cancer diagnosis and treatment.

show abstract

“…[3] Since the abnormal metabolism of cancer cells, the tumor microenvironment has higher concentration of reactive oxygen specials (ROS) and glutathione (GSH), lower pH value, higher expression of matrix metalloproteinase than in normal tissues microenvironment. [4] Based on the special tumor microenvironment, various stimuli-responsive nanoscale drug delivery systems have been designed and developed, which obviously enhanced the anticancer effect of small molecular chemotherapy drugs by rapidly release of drug in tumor site via spatiotemporal controllably means. [5] ROS-responsive nanoscale drug delivery systems has drawn great attention of researchers, and lots of ROS-responsive nanoscale drug delivery systems has been constructed, which markedly enhanced the cancer treatment effect in some extent.…”

Section: Introductionmentioning

confidence: 99%

Construction of Polymeric Micelles for Improving Cancer Chemotherapy by Promoting the Production of Intracellular Reactive Oxygen Species and Self‐Accelerating Drug Release

Han

Liu

et al. 2021

ChemistrySelect

View full text Add to dashboard Cite

Lots of efforts have been devoted to enhancing the antitumor efficacy of reactive oxygen species (ROS)-responsive nanoscale drug delivery systems. Here, a ROS-responsive amphiphilic polymer (mPEG-b-poly(thioacetal-thioether), P2) with property of generation and self-sustained high level of ROS, and a control material mPEG-b-poly(ester-thioether) (P1) were constructed and characterized by proton nuclear magnetic resonance ( 1 H NMR). The two polymers could self-assemble into micelles and the doxorubicin loading content of P1 and P2 micelles were 13.08 % and 13.51 %, respectively. The two polymers could self-assemble into micelles and exhibit good DOX loading capacity. ROS-responsiveness of P1 and P2 micelles was investigated by 1 H NMR, dynamic light scattering (DLS), and scanning electron microscope (SEM). The results of in vitro ROS detection indicated that P2 micelles could ROSresponsive release of cinnamaldehyde, and promote intracellular generation of ROS and maintain high level of ROS. DOX/P1 micelle shown comparable in vitro antitumor efficacy with DOX/P2 micelle, and a slightly lower IC50 value was due to DOX/P1 micelle has faster cell internalization, poorer micelle stability and integrality. Considering the stability of the nanoparticle circulation in vivo, the DOX/P2 micelle containing both thioether and thioacetal would be more suitable and could show better in vivo antitumor efficacy.

show abstract

Endogenous tumor microenvironment-responsive multifunctional nanoplatforms for precision cancer theranostics

Cited by 25 publications

References 393 publications

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

HOCl‐Activated Aggregation of Gold Nanoparticles for Multimodality Therapy of Tumors

Construction of Polymeric Micelles for Improving Cancer Chemotherapy by Promoting the Production of Intracellular Reactive Oxygen Species and Self‐Accelerating Drug Release

Contact Info

Product

Resources

About